1. Alkaloid derivative ION-31a inhibits breast cancer metastasis and angiogenesis by targeting HSP90α.
- Author
-
Ni, Tian-Wen, Duan, Xiao-Chuan, Wang, Meng, Jia, Mei-Qi, Chen, Ying, Yu, Yang, Qin, Nan, and Duan, Hong-Quan
- Subjects
- *
METASTATIC breast cancer , *FOCAL adhesion kinase , *PROTEIN kinase B , *BREAST cancer , *ENDOTHELIAL growth factors , *ISOQUINOLINE alkaloids , *HYPOXIA-inducible factor 1 , *HEAT shock proteins - Abstract
[Display omitted] • Chiral ionone alkaloid ION-31a inhibits breast cancer metastasis and angiogenesis. • Its direct target was identified as HSP90α. • ION-31a downregulates HSP90/HIF-1α/VEGF/VEGFR2 pathway. Breast cancer has become the number one killer of women. In our previous study, an active compound, ION-31a, with potential anti-metastasis activity against breast cancer was identified through the synthesis of ionone alkaloid derivatives. In the present study, we aimed to identify the therapeutic target of ION-31a. We used a fluorescence tag labeled probe, molecular docking simulation, and surface plasmon resonance (SPR) analysis to identify the target of ION-31a. The main target of ION-31a was identified as heat shock protein 90 (HSP90). Thus, ION-31a is a novel HSP90 inhibiter that could suppress the metastasis of breast cancer and angiogenesis significantly in vitro and in vivo. ION-31a acts via inhibiting the HSP90/hypoxia inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway and downregulating downstream signal pathways, including protein kinase B (AKT)/mammalian target of rapamycin (mTOR), AKT2/protein kinase C epsilon (PKCζ), extracellular regulated kinase 1/2 (ERK1/2), focal adhesion kinase (FAK), and mitogen-activated protein kinase 14 (p38MAPK) pathways. ION-31a affects multiple effectors implicated in tumor metastasis and has the potential to be developed as an anti-metastatic agent to treat patients with breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF